Daridorexant
- Generic Name
- Daridorexant
- Brand Names
- Quviviq
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23ClN6O2
- CAS Number
- 1505484-82-1
- Unique Ingredient Identifier
- LMQ24G57E9
- Background
Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with c...
- Indication
In the US and Europe, daridorexant is indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. The European prescribing information states that insomnia should be characterized by symptoms that are present for at least three months and have a considerable impact on daytime functionin...
- Associated Conditions
- Insomnia
- Associated Therapies
- -
A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04250506
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04024332
- Locations
- 🇩🇪
APEX GmbH, München, Germany
A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT03892902
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03799978
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT03765294
- Locations
- 🇩🇪
Advanced Sleep Research, Berlin, Germany
Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users
- Conditions
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT03657355
- Locations
- 🇨🇦
Altasciences Company Inc., Montreal, Canada
🇺🇸Altasciences Clinical Kansas, Inc. (former Vince and Associates Clinical Research, Inc.), Overland Park, Kansas, United States
A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT03646864
- Locations
- 🇩🇪
framol-med GmbH, Lungenpraxis, Rheinau, Germany
🇩🇪Advanced Sleep Research, Berlin, Germany
🇩🇪ZMS, Warendorf, Germany
A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT03609775
- Locations
- 🇳🇱
Centre For Human Drug Research, Leiden, Netherlands
Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 924
- Registration Number
- NCT03575104
- Locations
- 🇨🇦
Canadian Phase Onward Inc., Toronto, Ontario, Canada
🇺🇸FutureSearch Trials of Neurology, LP, Austin, Texas, United States
🇺🇸Neurotrials Research Incorporated, Atlanta, Georgia, United States
A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03339752
- Locations
- 🇨🇿
Cepha s.r.o., Pilsen, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.